VYGR has been the subject of several other reports. Zacks Investment Research raised Voyager Therapeutics from a sell rating to a hold rating in a report on Saturday, August 11th. Morgan Stanley reissued an equal weight rating and issued a $27.00 price objective on shares of Voyager Therapeutics in a report on Monday, September 10th. ValuEngine raised Voyager Therapeutics from a hold rating to a buy rating in a report on Tuesday. BidaskClub raised Voyager Therapeutics from a sell rating to a hold rating in a report on Saturday, September 29th. Finally, HC Wainwright set a $30.00 price objective on Voyager Therapeutics and gave the company a buy rating in a report on Wednesday, August 8th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $28.00.
Voyager Therapeutics stock traded up $0.02 during midday trading on Thursday, hitting $12.33. The stock had a trading volume of 18,350 shares, compared to its average volume of 299,649. The firm has a market cap of $442.10 million, a P/E ratio of -4.67 and a beta of 3.15. Voyager Therapeutics has a 12 month low of $11.00 and a 12 month high of $31.91.
In related news, Director Glenn Pierce bought 5,000 shares of the firm’s stock in a transaction on Wednesday, September 12th. The stock was bought at an average cost of $18.44 per share, for a total transaction of $92,200.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James A. Geraghty bought 3,000 shares of the firm’s stock in a transaction on Friday, August 17th. The stock was bought at an average price of $18.31 per share, with a total value of $54,930.00. Following the completion of the purchase, the director now owns 73,588 shares of the company’s stock, valued at $1,347,396.28. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 11,000 shares of company stock valued at $205,300. 33.60% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of VYGR. Northern Trust Corp boosted its position in shares of Voyager Therapeutics by 3.2% during the first quarter. Northern Trust Corp now owns 200,378 shares of the company’s stock worth $3,765,000 after buying an additional 6,276 shares during the period. BlackRock Inc. boosted its position in shares of Voyager Therapeutics by 18.8% during the first quarter. BlackRock Inc. now owns 1,438,029 shares of the company’s stock worth $27,020,000 after buying an additional 227,266 shares during the period. UBS Group AG acquired a new position in shares of Voyager Therapeutics during the first quarter worth approximately $684,000. Acadian Asset Management LLC boosted its position in shares of Voyager Therapeutics by 919.8% during the second quarter. Acadian Asset Management LLC now owns 32,747 shares of the company’s stock worth $640,000 after buying an additional 29,536 shares during the period. Finally, Hershey Trust Co. acquired a new position in shares of Voyager Therapeutics during the second quarter worth approximately $284,000. Institutional investors and hedge funds own 85.09% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Further Reading: What is a conference call?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.